hereditary angioedema Archives -

BioCryst Pharma’s Orladeyo has been recommended by NICE as a treatment for the rare disease hereditary angioedema (HAE)

NICE backs BioCryst’s Orladeyo for hereditary angioedema

https://pharmaphorum.com/news/nice-backs-biocrysts-orladeyo-for-hereditary-angioedema/

CSL Behring has filed a lawsuit against a former employee, claiming he stole sensitive information with the intention

CSL accuses ex-exec, now at Pharming, of stealing trade secrets

https://pharmaphorum.com/news/csl-accuses-ex-exec-now-at-pharming-of-stealing-trade-secrets/

Patients in England and Wales with hereditary angioedema (HAE) should soon have a new treatment option after NICE

HAE patients get new option as NICE backs Takeda’s Takhzyro

https://pharmaphorum.com/news/hae-patients-get-new-option-as-nice-backs-takedas-takhzyro/

The FDA has rejected Pharming’s application to expand the licence of Ruconest, for a use as prophylaxis for

FDA rejects Pharming’s Ruconest HAE label expansion

https://pharmaphorum.com/news/fda-rejects-pharmings-ruconest-hae-label-expansion/

The FDA has approved Shire’s first antibody-based preventive treatment for the rare disease hereditary angioedema, raising hopes for

Shire eyes blockbuster sales as FDA approves HAE therapy

https://pharmaphorum.com/news/shire-eyes-blockbuster-sales-as-fda-approves-hae-therapy/

Lanadelumab could revolutionise treatment of swelling disease.

Shire plans filing for HAE drug after phase 3 success

https://pharmaphorum.com/news/shire-plans-filing-hae-drug-phase-3-success/

hereditary angioedema